Today's Rundown - Gilead's remdesivir looks promising in leaked early results, but don't jump to conclusions: analysts
- White House details guidelines for businesses, hospitals to get back to 'normality'
- After 'superspreader' meeting, recovered Biogen employees give blood to aid coronavirus research
- Don't count on a COVID-19 vaccine for at least 5 years, says AI-based forecast
- Resuming elective procedures will depend on testing, PPE, decline of COVID-19 cases, providers say
- Oklahoma, Texas and Alaska to begin allowing elective surgeries
- Biopharma roundup: Vaccines could take years, forecast says; Sanofi aims for smartphone test
- Healthcare roundup: Mount Sinai, UPMC Children's get initial FCC telehealth funding; ACAP urges CMS to adopt policy changes
- Roche slates COVID-19 antibody blood test for early May
- CDC plans to roll out app in May to speed up COVID-19 case reporting
- Sanofi taps Luminostics to develop a smartphone-based COVID-19 test
- CVS Health to work with UCLA Health, other hospitals to create more bed capacity
- Bayer version of COVID-19 antimalarial hopeful may come with quality concerns: report
- MD Anderson research freeze stops production of Bellicum drugs
- Stalled by COVID-19, teens from BioMarin-backed hemophilia musical reunite remotely
Featured Story | | | Thursday, April 16, 2020 The world is watching and waiting for data to see whether Gilead's investigational antiviral remdesivir can help fight COVID-19. And while some leaked early results suggest that it can, industry watchers will need to wait for data from Gilead's own controlled phase 3 study to know for sure. |
|
|---|
|
Top Stories Thursday, April 16, 2020 Here's what the President and top advisors are saying about what the guidelines mean for nursing homes, surgery centers and hospitals. Friday, April 17, 2020 Early in the U.S. COVID-19 outbreak, Biogen’s February meeting in Boston played a central role in spreading the virus in Massachusetts and beyond. Now that many employees have recovered, they’re donating blood samples to a “biobank" to help researchers learn more about the virus. Friday, April 17, 2020 Could a COVID-19 vaccine really be ready in 12 to 18 months? Global analytics firm Clarivate applied machine learning to leading vaccine candidates from Moderna and Inovio and made some sobering forecasts about both the FDA approval timeline and the probability of success. Friday, April 17, 2020 Here's when provider groups say about when and how facilities can resume elective procedures. Friday, April 17, 2020 Texas and Alaska are among the first states to begin reopening their economies, including allowing elective surgeries to resume, following the release of new guidance from the White House this week. Friday, April 17, 2020 Despite researchers holding out hope that a COVID-19 vaccine could hit the market faster than expected, one forecast warns that a shot might not be available for at least five years. Global analysts firm Clarivate said two vaccine candidates from Moderna and Inovio could be years in the making––even if they're successful. Friday, April 17, 2020 FierceHealthcare's ongoing coverage of how the coronavirus is impacting the healthcare industry. Friday, April 17, 2020 Roche announced plans to launch its own COVID-19 antibody blood test early next month as a complement to its previous high-throughput test for active infections authorized by the FDA in March. Friday, April 17, 2020 The Centers for Disease Control and Prevention (CDC) plans to roll out an app in May that will accelerate electronic case reporting of COVID-19 cases. The app will enable public health agencies to get accurate, real-time data on COVID-19 cases to support case management and contact tracing efforts, the CDC said. Friday, April 17, 2020 Sanofi has begun working with California startup Luminostics to build an at-home test for COVID-19 that would use a sample reader powered by a user’s personal smartphone. Friday, April 17, 2020 In a move to help increase hospital bed capacity, CVS Health will provide in-home nursing to support the transition to eligible IV-therapy patients out of the hospital. Friday, April 17, 2020 Drugmakers are rushing to supply millions of doses of hydroxychloroquine, a cheap generic in testing as a possible treatment for COVID-19, after public interest sent demand through the roof. But donated batches of the drug from Bayer, which haven't been approved by the FDA, are drawing quality concerns. Friday, April 17, 2020 The cessation of research at MD Anderson Cancer Center has put a stop to production of Bellicum Pharmaceuticals’ clinical development candidates. Friday, April 17, 2020 For the teens involved in the BioMarin-sponsored “Hemophilia the Musical” arts program, the show must go on in spite of COVID-19. That’s the message they’re sending on World Hemophilia Day Friday as they reunite remotely while sheltering in place. |
|
